TLR4 and neuropathy: We sought to identify new therapeutic targets for the treatment of VIPN by combining behavioral experiments, histological examination and pharmacology, and found that vincristine-induced neuropathy develops predominantly due to neuro-inflammatory interactions involving Toll-like receptor 4 signaling.